 Novartis NVS , Financial has launched some of the most novel therapeutics over the past five years, and yet it sells at just a few dollars above its 52-week low, has a trailing 12-month price-earnings ratio of just 7.50 and pays a dividend that yields 4.37. Shares of Novartis have lost 11.8 so far this year compared with the industrys decline of 5. 